Outcomes in COVID-19 pemivibart studies
Outcomes in pemivibart studies. mAb use may create new variants that spread globally
Focosi , Leducq , and may be associated with prolonged viral loads, clinical deterioration, and immune escape
Casadevall , Choudhary , Günther , Leducq .
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ CANOPY Wolfe (RCT) -150% 2.50 [0.10-61.1] death 1/317 0/160 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.59 Prophylaxis -150% 2.50 [0.10-61.1] 1/317 0/160 150% higher risk All studies -150% 2.50 [0.10-61.1] 1/317 0/160 150% higher risk 1 pemivibart COVID-19 study c19 earlyNovember 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.59 Effect extraction pre-specified (most serious outcome) Favors pemivibart Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ CANOPY Wolfe (RCT) -150% 2.50 [0.10-61.1] 1/317 0/160 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.59 Prophylaxis -150% 2.50 [0.10-61.1] 1/317 0/160 150% higher risk All studies -150% 2.50 [0.10-61.1] 1/317 0/160 150% higher risk 1 pemivibart COVID-19 mortality result c19 earlyNovember 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.59 Favors pemivibart Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ CANOPY Wolfe (RCT) 75% 0.25 [0.01-6.13] hosp. 0/317 1/160 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.4 Prophylaxis 75% 0.25 [0.01-6.13] 0/317 1/160 75% lower risk All studies 75% 0.25 [0.01-6.13] 0/317 1/160 75% lower risk 1 pemivibart COVID-19 hospitalization result c19 earlyNovember 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.4 Favors pemivibart Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ CANOPY Wolfe (RCT) -150% 2.50 [0.10-61.1] death 1/317 0/160 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.59 Prophylaxis -150% 2.50 [0.10-61.1] 1/317 0/160 150% higher risk All studies -150% 2.50 [0.10-61.1] 1/317 0/160 150% higher risk 1 pemivibart COVID-19 serious outcome c19 earlyNovember 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.59 Effect extraction pre-specified (most serious outcome) Favors pemivibart Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ CANOPY Wolfe (RCT) 76% 0.24 [0.13-0.45] symp. case 14/317 29/160 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p < 0.0001 Prophylaxis 76% 0.24 [0.13-0.45] 14/317 29/160 76% lower risk All studies 76% 0.24 [0.13-0.45] 14/317 29/160 76% lower risk 1 pemivibart COVID-19 case result c19 earlyNovember 2024 Tau2 = 0.00, I2 = 0.0%, p < 0.0001 Favors pemivibart Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ CANOPY Wolfe (RCT) -150% 2.50 [0.10-61.1] death 1/317 0/160 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.59 Prophylaxis -150% 2.50 [0.10-61.1] 1/317 0/160 150% higher risk All studies -150% 2.50 [0.10-61.1] 1/317 0/160 150% higher risk 1 pemivibart COVID-19 Randomized Controlled Trials c19 earlyNovember 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.59 Effect extraction pre-specified (most serious outcome) Favors pemivibart Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ CANOPY Wolfe (RCT) -150% 2.50 [0.10-61.1] 1/317 0/160 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.59 Prophylaxis -150% 2.50 [0.10-61.1] 1/317 0/160 150% higher risk All studies -150% 2.50 [0.10-61.1] 1/317 0/160 150% higher risk 1 pemivibart COVID-19 RCT mortality result c19 earlyNovember 2024 Tau2 = 0.00, I2 = 0.0%, p = 0.59 Favors pemivibart Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ CANOPY Wolfe (RCT) -150% 2.50 [0.10-61.1] death 1/317 0/160 Improvement, RR [CI] Treatment Control CANOPY Wolfe (RCT) 75% 0.25 [0.01-6.13] hosp. 0/317 1/160 CANOPY Wolfe (RCT) 74% 0.26 [0.14-0.47] progression 15/317 29/160 CANOPY Wolfe (RCT) 76% 0.24 [0.13-0.45] symp. case 14/317 29/160 Pemivibart COVID-19 outcomes c19 earlyNovember 2024 Favors pemivibart Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
